Looking back at 2025: top content on RegMedNet
2025 was a year of incredible progress and innovation in regenerative medicine, marked by groundbreaking approvals, thought-provoking interviews and impactful content loved by you, our readers. It was a year where science and collaboration came together to push the boundaries of what’s possible, offering new hope for patients and advancing the field in monumental ways.
From exploring the promising results of clinical trials to uncovering cutting-edge advances, technology and techniques, 2025 was truly an impactful year.
Let’s take a look back at some of the most popular and impactful stories, interviews and features that defined the year.
Top news
Jumpstarting brain repair: promising stem cell therapy for ischemic stroke
One of the most-read news articles of 2025 highlighted the potential of SB623, a stem cell therapy for ischemic stroke. Researchers at the Gladstone Institutes (CA, USA) investigated this allogeneic, modified bone marrow-derived human mesenchymal cell therapy, developed by SanBio (Tokyo, Japan). The study examined the effects of SB623 on brain excitability, brain tissue, and peripheral blood during the chronic stage following ischemic stroke.
CRISPR-based gene therapy shows promise for muscular dystrophy
CRISPR technology continues to revolutionize gene editing, offering new possibilities for addressing genetic disorders. This year, we reported on how researchers from the Experimental and Clinical Research Center (Berlin, Germany) developed a gene-editing technique to repair and restore protein deficiencies caused by mutations associated with muscular dystrophy.
Cell therapy weekly: US$286 million acquisition expands CAR-T manufacturing and commercialization
Among the diverse range of news that interested our readers, our Cell therapy weekly roundups stood out as a favorite. Earlier this year, Bristol Myers Squibb acquired 2seventy bio for $286 million, gaining sole responsibility for Abecma – a CAR-T cell therapy for relapsed or refractory multiple myeloma. We also covered the partnership between RoslinCT and Ayrmid Pharma, as well as AskBio dosing the first patient in the second cohort of its Phase I/II LION-CS101 trial for AB-1003, a gene therapy for limb-girdle muscular dystrophy.
Cell therapy weekly keeps you informed with concise summaries of the top industry news every week. Check out the archive here.
Top interviews
Cell therapies for autoimmune diseases: a podcast with Lindsay Davies
In celebration of International Women’s Day, Lindsay Davies joined us for a podcast episode to discuss the evolving role of cell therapies in treating autoimmune diseases. She emphasized the importance of tailoring therapies based on disease type, stage and patient profile to achieve optimal outcomes. Additionally, she highlighted how growing evidence of sex-related differences will increasingly shape decisions in the development and testing of cell therapies.
Pick of the posters: ESGCT 2025
Conference coverage offers our members a chance to experience events they may not be able to attend, while also exploring the scientific breakthroughs driving the field forward. This year, we attended the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT; October 7–10; Seville, Spain). Among the standout posters were studies on preclinical approaches for Merosin-deficient congenital muscular dystrophy type 1A using mesenchymal stromal cells and the engineering of a non-viral glucose-responsive gene system.
View the events to look forward to next year on our events page.
Scientific progress is driven by dedicated individuals whose unique stories shape the field. Oncology Medical Science Liaison Henry J Henderson III shared pivotal moments from his career, reflected on the importance of cancer awareness, and discussed how his oncology background informs his work in medical affairs. Each individual’s story is unique in how they enter research and what ‘change’ and impact mean to them. While understanding science is an incredible opportunity, getting to know the people behind the research – their journeys, motivations and roles – is even more inspiring. Henry’s insights offered a glimpse into the passion and dedication that drive innovation and the human element that fuels progress in the field.
Top sponsored features
Webinar: Bridging platforms for enhanced & harmonized bioprocess data collaboration
In this webinar, Benjamin Wolters, a research scientist at the Eppendorf Bioprocess Center (Jülich, Germany) provided insights into the benefits of a platform bridging tools like the Eppendorf BioNsight® cloud solution for efficient bioprocess data management.
Infographic: Challenges and considerations in allogeneic cell therapy manufacturing
Allogeneic cell therapy offers a scalable and efficient approach to regenerative medicine by utilizing cells from healthy donors. Unlike autologous therapies which rely on a patient’s own cells, allogeneic approaches allow for off-the-shelf availability and rapid clinical deployment. This infographic explored the types of cells used in allogeneic cell therapies, highlighting their applications and the challenges of ensuring safety, consistency and scalability.
eBook: Gene therapy analytical testing
Our Spotlight feature on gene therapy analytical testing provided insights, the latest news and expert perspectives. This eBook compiled highlights from the feature, along with additional resources and peer-reviewed articles focused on improving the standardization of plasmid DNA as a starting material for advanced therapies, particularly in the development of gene therapies and adeno-associated virus-based treatments.
Top features
FDA-approved cell and gene therapies
One of the year’s standout features examined FDA-approved cell and gene therapies, all in one place. It serves as a valuable resource for understanding the diversity and progress in the field. Whether you are a researcher, healthcare professional, or simply interested in the latest advancements, exploring this table will provide insights into the groundbreaking technologies shaping the future of medicine.
We aim to keep you updated on the latest developments in the field, as well as the most cutting-edge information. This year, we explored how nanotechnology is revolutionizing regenerative medicine by enhancing drug delivery, accelerating wound healing and advancing tissue engineering. These advancements highlight the transformative potential of nanotechnology in addressing some of the most pressing challenges in regenerative medicine.
Industry updates with Dusko Ilic: August 2025
And lastly, every month Dusko Ilic provides industry updates, and his August installment was a highlight the year. He discussed the first-in-human transplantation of gene-edited pancreatic islet cells in a patient with long-standing type 1 diabetes (without immunosuppression), the emergence of pregnancy robots, and million-dollar cures.
You can read all of Dusko’s industry updates here or check out our eBook that compiled of his updates from 2024.
Looking back at 2024: top content on RegMedNet
View the top content from 2024, which included our milestone year as we celebrated 10 years of RegMedNet.
2025 was a year of progress, innovation, and collaboration in regenerative medicine. We look forward to continuing this journey with you in 2026!